The composite of cardiovascular death , MI , or stroke occurred in 824 in the darapladib group and 838 in the placebo group ( 15.0 % vs 15.0 % at 3 years ; HR , 0.99 [ 95 % CI , 0.90-1 .09 ] ; P = .78 ) .
